Clinical Trial Update: Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sunitinib for metastatic germ cell tumors that relapsed or were refractory to prior treatment; the study completed with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extragonadal Germ Cell Tumor
• Ovarian Cancer
• Teratoma
• Testicular Germ Cell Tumor

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Extragonadal Germ Cell Tumor, Ovarian Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-10-27